Sevuparin trial for acute pain in sickle cell disease: the dog that did not bark
- 1 May 2021
- journal article
- editorial
- Published by Elsevier in The Lancet Haematology
- Vol. 8 (5) , e307-e309
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Sevuparin for the treatment of acute pain crisis in patients with sickle cell disease: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trialThe Lancet Haematology, 2021
- Unfractionated heparin in acute chest syndrome: a pilot feasibility randomized controlled trial of unfractionated heparin vs. standard of care in acute chest syndromePilot and Feasibility Studies, 2020
- Early Initiation of Treatment with Rivipansel for Acute Vaso-Occlusive Crisis in Sickle Cell Disease (SCD) Achieves Earlier Discontinuation of IV Opioids and Shorter Hospital Stay: Reset Clinical Trial AnalysisBlood, 2020
- Drug Therapies for the Management of Sickle Cell DiseaseF1000Research, 2020
- Thromboinflammatory mechanisms in sickle cell disease - challenging the hemostatic balanceHaematologica, 2020
- Thrombin activation of PAR-1 contributes to microvascular stasis in mouse models of sickle cell diseaseBlood, 2020
- Leukocyte adhesion to P-selectin and the inhibitory role of Crizanlizumab in sickle cell disease: A standardized microfluidic assessmentBlood Cells, Molecules, and Diseases, 2020
- Therapeutic strategies for sickle cell disease: towards a multi-agent approachNature Reviews Drug Discovery, 2018
- Crizanlizumab for the Prevention of Pain Crises in Sickle Cell DiseaseNew England Journal of Medicine, 2017
- Crises in Sickle Cell DiseaseChest, 2016